vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and First Bancorp, Inc (FNLC). Click either name above to swap in a different company.

First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $13.0M, roughly 2.0× Aquestive Therapeutics, Inc.). First Bancorp, Inc runs the higher net margin — 39.4% vs -244.8%, a 284.2% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs 9.7%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-8.6M). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs 3.9%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.

AQST vs FNLC — Head-to-Head

Bigger by revenue
FNLC
FNLC
2.0× larger
FNLC
$25.8M
$13.0M
AQST
Growing faster (revenue YoY)
FNLC
FNLC
+7.9% gap
FNLC
17.5%
9.7%
AQST
Higher net margin
FNLC
FNLC
284.2% more per $
FNLC
39.4%
-244.8%
AQST
More free cash flow
FNLC
FNLC
$43.1M more FCF
FNLC
$34.6M
$-8.6M
AQST
Faster 2-yr revenue CAGR
FNLC
FNLC
Annualised
FNLC
18.1%
3.9%
AQST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AQST
AQST
FNLC
FNLC
Revenue
$13.0M
$25.8M
Net Profit
$-31.9M
$10.2M
Gross Margin
55.2%
Operating Margin
-221.6%
48.1%
Net Margin
-244.8%
39.4%
Revenue YoY
9.7%
17.5%
Net Profit YoY
-86.8%
39.7%
EPS (diluted)
$-0.26
$0.91

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
FNLC
FNLC
Q4 25
$13.0M
$25.8M
Q3 25
$12.8M
$24.5M
Q2 25
$10.0M
$22.5M
Q1 25
$8.7M
$21.8M
Q4 24
$11.9M
$22.0M
Q3 24
$13.5M
$20.5M
Q2 24
$20.1M
$19.2M
Q1 24
$12.1M
$18.5M
Net Profit
AQST
AQST
FNLC
FNLC
Q4 25
$-31.9M
$10.2M
Q3 25
$-15.4M
$9.1M
Q2 25
$-13.5M
$8.1M
Q1 25
$-22.9M
$7.1M
Q4 24
$-17.1M
$7.3M
Q3 24
$-11.5M
$7.6M
Q2 24
$-2.7M
$6.2M
Q1 24
$-12.8M
$6.0M
Gross Margin
AQST
AQST
FNLC
FNLC
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Q1 24
63.6%
Operating Margin
AQST
AQST
FNLC
FNLC
Q4 25
-221.6%
48.1%
Q3 25
-89.6%
45.2%
Q2 25
-113.6%
43.7%
Q1 25
-222.1%
39.3%
Q4 24
-114.4%
39.5%
Q3 24
-61.2%
44.6%
Q2 24
0.3%
38.8%
Q1 24
-74.3%
39.3%
Net Margin
AQST
AQST
FNLC
FNLC
Q4 25
-244.8%
39.4%
Q3 25
-120.6%
37.0%
Q2 25
-135.4%
35.8%
Q1 25
-263.0%
32.5%
Q4 24
-143.7%
33.1%
Q3 24
-85.0%
36.9%
Q2 24
-13.7%
32.1%
Q1 24
-106.4%
32.5%
EPS (diluted)
AQST
AQST
FNLC
FNLC
Q4 25
$-0.26
$0.91
Q3 25
$-0.14
$0.81
Q2 25
$-0.14
$0.72
Q1 25
$-0.24
$0.63
Q4 24
$-0.18
$0.66
Q3 24
$-0.13
$0.68
Q2 24
$-0.03
$0.55
Q1 24
$-0.17
$0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
FNLC
FNLC
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$27.5M
$95.5M
Stockholders' EquityBook value
$-33.7M
$283.1M
Total Assets
$160.4M
$3.2B
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
FNLC
FNLC
Q4 25
Q3 25
$129.1M
Q2 25
$60.5M
Q1 25
$68.7M
Q4 24
$71.5M
Q3 24
$77.9M
Q2 24
$89.9M
Q1 24
$95.2M
Total Debt
AQST
AQST
FNLC
FNLC
Q4 25
$27.5M
$95.5M
Q3 25
$45.0M
$95.5M
Q2 25
$45.0M
$95.0M
Q1 25
$45.0M
$70.0M
Q4 24
$32.5M
$95.0M
Q3 24
$45.0M
$95.0M
Q2 24
$45.0M
$70.0M
Q1 24
$45.0M
$70.0M
Stockholders' Equity
AQST
AQST
FNLC
FNLC
Q4 25
$-33.7M
$283.1M
Q3 25
$-4.1M
$274.6M
Q2 25
$-72.6M
$265.5M
Q1 25
$-60.9M
$259.7M
Q4 24
$-60.2M
$252.5M
Q3 24
$-45.4M
$256.8M
Q2 24
$-35.5M
$244.7M
Q1 24
$-36.3M
$242.6M
Total Assets
AQST
AQST
FNLC
FNLC
Q4 25
$160.4M
$3.2B
Q3 25
$163.6M
$3.2B
Q2 25
$93.7M
$3.2B
Q1 25
$102.2M
$3.2B
Q4 24
$101.4M
$3.2B
Q3 24
$110.0M
$3.1B
Q2 24
$117.6M
$3.1B
Q1 24
$129.5M
$3.0B
Debt / Equity
AQST
AQST
FNLC
FNLC
Q4 25
0.34×
Q3 25
0.35×
Q2 25
0.36×
Q1 25
0.27×
Q4 24
0.38×
Q3 24
0.37×
Q2 24
0.29×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
FNLC
FNLC
Operating Cash FlowLast quarter
$-8.5M
$37.8M
Free Cash FlowOCF − Capex
$-8.6M
$34.6M
FCF MarginFCF / Revenue
-65.7%
133.9%
Capex IntensityCapex / Revenue
0.7%
12.5%
Cash ConversionOCF / Net Profit
3.72×
TTM Free Cash FlowTrailing 4 quarters
$-53.0M
$55.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
FNLC
FNLC
Q4 25
$-8.5M
$37.8M
Q3 25
$-12.6M
$12.9M
Q2 25
$-7.9M
$7.4M
Q1 25
$-23.4M
$2.2M
Q4 24
$-6.5M
$26.0M
Q3 24
$-11.9M
$9.8M
Q2 24
$-7.0M
$6.4M
Q1 24
$-10.4M
$-1.5M
Free Cash Flow
AQST
AQST
FNLC
FNLC
Q4 25
$-8.6M
$34.6M
Q3 25
$-12.9M
$12.6M
Q2 25
$-8.0M
$7.2M
Q1 25
$-23.5M
$828.0K
Q4 24
$-6.5M
$24.6M
Q3 24
$-12.0M
$9.6M
Q2 24
$-7.0M
$6.3M
Q1 24
$-10.4M
$-1.8M
FCF Margin
AQST
AQST
FNLC
FNLC
Q4 25
-65.7%
133.9%
Q3 25
-100.6%
51.4%
Q2 25
-80.2%
32.1%
Q1 25
-269.9%
3.8%
Q4 24
-54.8%
111.7%
Q3 24
-88.3%
47.0%
Q2 24
-35.0%
32.9%
Q1 24
-86.4%
-9.8%
Capex Intensity
AQST
AQST
FNLC
FNLC
Q4 25
0.7%
12.5%
Q3 25
1.8%
1.2%
Q2 25
1.1%
0.6%
Q1 25
1.5%
6.2%
Q4 24
0.1%
6.7%
Q3 24
0.6%
0.5%
Q2 24
0.2%
0.3%
Q1 24
0.2%
1.8%
Cash Conversion
AQST
AQST
FNLC
FNLC
Q4 25
3.72×
Q3 25
1.42×
Q2 25
0.91×
Q1 25
0.31×
Q4 24
3.58×
Q3 24
1.29×
Q2 24
1.03×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons